March 19, 2023

Dear Rett Patient Advocacy Leaders,

Today, Taysha shared interim clinical data from the REVEAL Adolescent & Adult Study evaluating TSHA-102, our investigational gene therapy for Rett syndrome. Taysha also announced that TSHA-102 received Innovative Licensing and Access Pathway (ILAP) designation from the U.K. MHRA. Please find a summary of these updates below and a link to the press release **here**.

What are the interim findings in the REVEAL Adolescent & Adult Study?
It is important to note that we cannot make any conclusions on interim findings of a clinical trial until all enrolled subjects are dosed and evaluated for the duration of the study, and once all the data has been collected and analyzed. Making conclusions about interim data may not accurately predict the full risk/benefit profile of an investigational product.

- **Interim data collected in the REVEAL Adolescent & Adult Study (females age 12+) from the two participants in cohort one (low dose) showed:**
  - TSHA-102 was well-tolerated with no treatment-emergent serious adverse events (SAEs) as of 35 weeks following administration (participant one) and no treatment-emergent SAEs as of 19 weeks following administration (participant two)
  - Sustained and new clinical improvements were seen based on data collected to measure efficacy at the 6-month (participant one) and 12-week (participant two) time point following administration of TSHA-102

Taysha plans to share data from cohort one (low dose) of the REVEAL Pediatric Study mid-year this year and initial data from cohort two (high dose) of the REVEAL Adolescent & Adult and the REVEAL Pediatric Study in the second half of 2024.

What is the REVEAL Adolescent & Adult Study?
- The REVEAL Adolescent & Adult Study is a Phase 1/2 study designed to evaluate whether TSHA-102, the investigational gene therapy, is safe, whether it is tolerable, and whether there may be beneficial effects in females 12 years and older with Rett syndrome. The study is designed to evaluate two different dose levels to determine the highest tolerable dose of TSHA-102.
- The study is being conducted in Canada and Taysha recently announced the expansion of the ongoing trial into the U.S. Additional information and clinical trial sites will be posted at https://clinicaltrials.gov/study/NCT05606614 once available.

What is the REVEAL Pediatric Study?
- The REVEAL Pediatric Study is a Phase 1/2 study designed to evaluate whether TSHA-102, the investigational gene therapy, is safe, whether it is tolerable, and whether there may be beneficial effects in females 5-8 years old, with plans to expand to females 3-8 years old in future phases of the study. The study is designed to evaluate two different dose levels to determine the highest tolerable dose of TSHA-102.
- The study is being conducted in the U.S. and Taysha recently announced authorization from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to expand the ongoing trial into the U.K. Additional information and clinical trial sites will be posted at https://clinicaltrials.gov/study/NCT06152237 once available.

What is the U.K. MHRA Innovative Licensing and Access Pathway (ILAP)?

- The ILAP designation aims to facilitate patient access to novel treatments by accelerating time to market through opportunities for enhanced engagements with U.K. regulatory and other stakeholders.

Will families who live outside of the country where a study is taking place be eligible to participate?

- It is important to note that ultimately the Principal Investigator (the lead physician at a clinical trial site) will decide the eligibility of an individual patient for the clinical trial. Though this varies site to site, participants are typically selected for enrollment using several considerations, including proximity to the clinical site, which can limit cross-border participation.
- Rett families and/or their treating physician may contact a participating site directly to ask about potential trial participation.

Who can families contact for more information about the REVEAL Adolescent & Adult Study (females age 12+)?

- Families can contact one of the participating clinical trial sites whose contact information is available at https://clinicaltrials.gov/study/NCT05606614. Additional trial sites will be posted as they become active.

Who can families contact for more information about the REVEAL Pediatric Study (females age 3-8)?

- Families can contact one of the participating clinical trial sites whose contact information is available at https://clinicaltrials.gov/study/NCT06152237.

If you have any general questions or would like to connect with someone from the Taysha Patient Affairs team, please contact patientaffairs@tayshagtx.com. If your healthcare provider would like to connect with a member of our Taysha Medical Affairs team, please ask them to contact medinfo@tayshagtx.com.

We would like to thank the entire Rett community and the Rett patient advocacy groups for your continued partnership. We would also like to acknowledge the individuals and families who choose to participate in research to help better understand the potential of gene therapy for Rett syndrome.

We look forward to sharing more information as it is publicly available.

Sincerely,
The Taysha Patient Affairs Team